Chongkundang is a pharmaceutical company established in 1941 that develops, manufactures, and markets prescription and over-the-counter medicines. The company's portfolio includes proprietary drugs, improved new drugs, generics, and biosimilars, with key products including the anticancer agent Camto, the diabetes treatment Duvie, the natural medicine Jitec, and the biosimilars Nesvel and Lucenvis. It maintains active research and development programs in targeted cancer therapies, antibody-drug conjugates, and gene therapy, and has entered into a technology licensing agreement with Novartis for the HDAC6 inhibitor CKD-510. Chongkundang serves domestic and international markets, including Japan, Vietnam, and Indonesia, through its own distribution networks and partnerships.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage ckdpharm.com
Sector Healthcare IR page —
Tags
prescription drugs, over-the-counter drugs, biosimilars, oncology, diabetes, antibody-drug conjugates, gene therapy, natural medicines, hdac6 inhibitors, Camto, Duvie, Jitec, Nesvel, Lucenvis, CKD-510, CKD-702, CKD-703, CKD-704, CKD-706, CKD-508, CKD-512, CKD-11101, CKD-701, CKD-943, CKD-950, CKD-951, CKD-920, CKD-101, Penzal, Prepmin, Eaton Q, Sokcheong, Gliatin, Dilatren, Zanuvia, Zanumet, Steglujan, Stelattro, Nexavar, Stivarga, Wegovy, Verkuvo, Eylea, Pexula, Adalat Oros, Aspirin Protect, Neurapec, Braining, Karendia, Boreng Flu V Tetra, Bio Spike Guard, Godeks, MIND STIM+, Prevena 20, Tedopi, Namodenoson, IFN-K, Lobeglitazone, Senvido
Press page —

Metrics

Valuation  
Market cap ₩ 1.224T
Market cap (USD) $ 900.926M
P/E 14.71
PEG —
P/BV 1.21
P/S 0.69
P/OCF 9.93
P/FCF -18.71
Dividend yield —
Turnover / mcap —
Returns  
ROE 8.2%
ROI 7.7%
ROIC 7.7%
Profit margin 4.6%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) -1.4%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) —
Quality score 0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Revenue 1.692T 1.586T 1.669T 1.488T 1.344T 1.303T 1.079T 956.219B 884.363B 831.986B 592.493B 544.13B 86.318B
Net profit 77.509B 109.073B 212.521B 80.953B 42.72B 91.633B 53.882B 42.399B 53.807B 40.946B -6.773B 35.154B 4.417B
Free cash flow -73.558B 25.815B 276.942B 22.836B -35.339B — — — — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013
Share price 86.207K 95.491K — — — — — — — — — — —
Price performance 12m -0.1 — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (KRW) 197B 192B 191B 174B 183B 204B 248B 270B 267B 266B
↳ YoY growth +18.6% -2.1% -0.7% -8.9% +5.3% +11.1% +22.0% +8.5% -1.1% -0.3%
↳ 5y CAGR +2.0% +0.7% +5.2% +7.1% +8.9% +7.7%
Other receivables (KRW) 12.9B 17.5B 16.7B 23.3B 35.8B 24.6B 30.9B 39.4B — —
Borrowings, current (KRW) 84.6B 81.1B 58.6B 89.5B 76B 99.3B 124B 182B 66.5B 163B
Borrowings, non-current (KRW) 40B 21.4B 45.9B 21.5B 55B 134B 111B 30B 116B 195B
Lease liabilities (KRW) — — — 7.01B 5.16B 3.47B 1.69B 8.06B 5.7B 9.73B
Cash and deposits (KRW) 21.7B 45.5B 45.9B 76.9B 124B 132B 117B 220B 228B 216B
Intangible assets (KRW) 14.9B 14.3B 15.4B 15.9B 19B 20.8B 27B 52.5B 75.6B 108B
Right-of-use assets (KRW) — — — 6.92B 5.04B 3.36B 1.66B 7.9B 5.48B 9.56B
Net debt (borrowings + leases - cash) (KRW) 18.3B 57B 58.5B 41.1B 12.5B 105B 118B 118M -40.3B 152B
Cash flow detail
Operating cash flow (KRW) 57.8B 81.7B 42.6B 77.3B 104B 12.9B 67.7B 318B 64.3B 67.4B
Purchases of property, plant and equipment (KRW) — — — — — -48.2B -44.9B -41.2B -38.5B -141B
Purchases of intangible assets (KRW) — — — — — -3.6B -8.17B -27.6B -27.6B -38.2B
Dividends paid (cash effect) (KRW) — — — — — -10.8B -11.2B -11.6B -13.3B -13.8B
Share buybacks (cash effect) (KRW) — — — — — — -1.89B -6.02B -16B -1.77B
Interest paid (cash effect) (KRW) -4.17B -3.54B -2.78B -2.94B -3.64B -3.76B -6.44B -8.63B -7.65B -6.23B
Income taxes paid (cash effect) (KRW) -12.7B -19B -27.5B -22B -18.3B -51.7B -15.6B -11.8B -34.9B -23.8B
Free cash flow (OCF - PPE - intangibles) (KRW) — — — — — -38.9B 14.7B 249B -1.81B -112B
Income detail
Research and development expense (KRW) — — — — — 163B 176B 140B 144B 154B
Total comprehensive income (KRW) 45.3B 55.7B 40.1B 53.3B 88.7B 38.7B 84.5B 212B 110B 118B
Comprehensive income to owners (KRW) 45.3B 55.9B 40.8B 54.1B 89.9B 39B 85.4B 211B 108B 118B
Reported Apr 2, 2018 Apr 2, 2018 Apr 1, 2019 Mar 30, 2020 Mar 18, 2021 Mar 20, 2024 Mar 25, 2025 Mar 25, 2025 Mar 25, 2025 Mar 18, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

[기재정정]분기보고서 (2026.09) Bull 0 Bear 0 Routine
리포덱스정 허가사항 변경 (전 용량) Bull 0 Bear 0 Routine
리포덱스캡슐 150MG 허가사항 변경 Bull 0 Bear 0 Clinical/regulatory

Prompts

CHONGKUNDANG (ticker 185750), listed in South Korea.

ETFs Holding CHONGKUNDANG

ETF Weight in ETF Shares Market value As of
AVEE 0.04% 1,018 $ 46.478K Nov 16, 2026
AVEM 0.01% 29,512 $ 1.347M Nov 16, 2026
AVES 0.01% 2,099 $ 95.832K Nov 16, 2026
DFEV 0.01% 3,932 $ 190.918K Nov 12, 2026
DFSE 0.01% 857 $ 41.612K Nov 12, 2026
DFEM 0.01% 9,687 $ 470.352K Nov 12, 2026
DEXC 0.01% 275 $ 13.353K Nov 12, 2026
DFAE 0.00% 6,673 $ 324.008K Nov 12, 2026
DFAX 0.00% 5,980 $ 290.359K Nov 12, 2026
AVXC 0.00% 240 $ 10.958K Nov 16, 2026